NFE2L2 and diabetic kidney disease: The synthetic Bardoxolone Methyl (BM), a Nrf2 agonist, was used in a phase III trial to prevent diabetic nephropathy, but the trial was discontinued owing to severe renal and cardiovascular toxicity in patients [40].